Contact phase inhibitors: the future of anticoagulation?
Open Access
- 17 March 2025
- journal article
- research article
- Published by Walter de Gruyter GmbH in Journal of Laboratory Medicine
- Vol. 49 (3) , 97-106
Abstract
Thrombosis remains a major public health problem. Although traditional anticoagulants, vitamin K antagonists (VKAs) and direct oral anticoagulants (DOACs) have been used with success over the last decades for prevention of venous thromboembolism (VTE) and stroke in non-valvular atrial fibrillation (AF), their use exposes the patient to an increased risk of bleeding. To overcome these limitations, new approaches are exploring contact phase inhibitors, specifically targeting factors XI, XIa, XII, and XIIa. Contact phase inhibitors including antisense oligonucleotides, monoclonal antibodies, small peptidomimetic molecules, aptamers and natural inhibitors seem promising in term of efficacy and safety. A common assay can be used to measure the anticoagulant activity of different drugs within a same pharmacological class (INR for VKAs) or even across different pharmacological classes (anti-Xa for all heparins and for direct factor Xa inhibitors). Because of the diversity of contact phase inhibitors, no specific common assay has been proposed so far. Activated partial thromboplastin time (aPTT) could play a role in the assessment of these new anticoagulants, but its relevance need to be confirmed. We aim at providing an overview of the pharmacological properties of contact phase inhibitors, the safety and efficacy outcomes from clinicals trials, as well as the possible coagulation assays relevant for patient follow-up.Keywords
This publication has 56 references indexed in Scilit:
- Development of new anticoagulant in 2023: Prime time for anti-factor XI and XIa inhibitorsJMV-Journal de Médecine Vasculaire, 2023
- News at XI: moving beyond factor Xa inhibitorsJournal of Thrombosis and Haemostasis, 2023
- Efficacy and Safety of Garadacimab in Combination with Standard of Care Treatment in Patients with Severe COVID-19Lung, 2023
- Single-Dose Pharmacokinetics of Milvexian in Participants with Mild or Moderate Hepatic Impairment Compared with Healthy ParticipantsClinical Pharmacokinetics, 2022
- Evaluation of thrombin generation assay in factor XI deficiencyClinica Chimica Acta, 2021
- Phase 2 Study of the Factor XI Antisense Inhibitor IONIS-FXIRx in Patients With ESRDKidney International Reports, 2021
- PK/PD modeling of FXI antisense oligonucleotides to bridge the dose‐FXI activity relation from healthy volunteers to end‐stage renal disease patientsCPT: Pharmacometrics & Systems Pharmacology, 2021
- Detecting factor XIa in immune globulin products: Commutability of international reference materials for traditional and global hemostasis assaysResearch and Practice in Thrombosis and Haemostasis, 2020
- Effect of Osocimab in Preventing Venous Thromboembolism Among Patients Undergoing Knee ArthroplastyJAMA, 2020
- BAY 1213790, a fully human IgG1 antibody targeting coagulation factor XIa: First evaluation of safety, pharmacodynamics, and pharmacokineticsResearch and Practice in Thrombosis and Haemostasis, 2019